Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2017

View Archived Issues

Crestovo initiates phase III trial of CP-101 to prevent C. difficile infection

KemPharm reveals new ADHD candidate

KIAA0125 found as an unfavorable prognostic marker in acute myeloid leukemia

New zebrafish Fanconi anemia-like model developed

FDA grants orphan drug designation for ABO-201 juvenile Batten disease gene therapy program

Alcyone Lifesciences and Pfizer enter feasibility study agreement

Gene-edited hematopoietic stem/progenitor cells created for SCID-X1

Paion completes phase III program for remimazolam for procedural sedation

Alkermes reports phase III data on ALKS-3831 in schizophrenia

Auspherix patents gold complexes for treating bacterial infections

Endpoints met in Lee's phase Ib/IIa study of adapalene/clindamycin gel for acne

Merck & Co. presents oxysterols receptor LXR-beta agonists

FORWARD II finds mirvetuximab soravtansine safe in combination therapies for ovarian cancer

Luc Therapeutics discloses NMDA receptor modulators

Research Triangle Institute divulges apelin receptor agonists

Janssen Pharmaceutica discovers BTK inhibitors

Cara Therapeutics reports phase IIb topline results on oral CR-845 for osteoarthritis pain

Heptares Therapeutics and PeptiDream enter inflammatory disease collaboration

Windtree reports topline phase IIb results for Aerosurf to treat RDS in premature infants

Sanpower Group completes Dendreon acquisition

FDA grants orphan drug designation to ganaxolone for CDKL5 disorder

FDA seeks to eliminate orphan drug designation request backlog

Acorda submits NDA for Inbrija to treat off episodes in Parkinson's disease

miR15a-5p identified as a biomarker of recurrence in colorectal carcinoma

Polatuzumab vedotin is eligible for access to EMA's PRIME program

Eiger Biopharmaceuticals selling Mydicar to Theragene Pharmaceuticals

FDA grants QIDP designation to Amphora for gonorrhea and bacterial vaginosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...